Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma

BACKGROUND: Medullary thyroid carcinoma (MTC) accounts for ∼5% of all thyroid malignancies. To date, surgery is the first-line therapy with curative intention. However, for advanced MTC, conventional chemotherapeutic agents do not provide convincing results. Therefore, the identification of biomarke...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Werner, Thomas A, Tamkan-Ölcek, Yasemin, Dizdar, Levent, Riemer, Jasmin C, Wolf, Achim, Cupisti, Kenko, Verde, Pablo E, Knoefel, Wolfram T, Krieg, Andreas
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4815780/
https://ncbi.nlm.nih.gov/pubmed/26882066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados